Compare AU
Compare DRUG vs. WDIV
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the SPDR S&P Global Dividend Fund (WDIV). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | WDIV | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 37 |
Median incremental investment | $967.00 | $658.36 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,905.75 | $2,496.12 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | WDIV | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | WDIV.AX was created on 2013-11-01 by SPDR. The fund's investment portfolio concentrates primarily on high dividend yield equity. The ETF currently has 274.33m in AUM and 96 holdings. The SPDR S&P Global Dividend Fund seeks to closely track, before fees and expenses, the returns of the S&P Global Dividend Aristocrats AUD Index. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | Altria Group Inc (2.72 %) Highwoods Properties Inc (2.39 %) Solvay SA (2.21 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Industrials (30.46 %) Real Estate (29.84 %) Consumer Staples (23.52 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (23.78 %) Canada (21.10 %) Japan (12.42 %) |
Management fee | 0.57 % | 0.35 % |
Key Summary
DRUG | WDIV | |
|---|---|---|
Issuer | BetaShares | SPDR |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | S&P Global Dividend Aristocrats Index sp_43 |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.35 % |
Price | $8.25 | $20.46 |
Size | $182.401 million | $278.795 million |
10Y return | N/A | 18.68 % |
Annual distribution yield (5Y) | 1.90 % | 4.85 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 04/11/2013 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | WDIV | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 37 |
Median incremental investment | $967.00 | $658.36 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,905.75 | $2,496.12 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | WDIV | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | WDIV |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |